Arkolith/Insider Trading/ENSC/Form 4

Kirkpatrick Lynn

Chief Executive Officer, DirectorEnsysce Biosciences, Inc. (ENSC) · full profile →Form 4 · filed Jul 2, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
1 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2021Grant(A)285K——285K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2021Grant(A)7K——7K
Jun 30, 2021Grant(A)461K——461K
Jun 30, 2021Grant(A)818K——818K
Jun 30, 2021Grant(A)659K——659K
Jun 30, 2021Grant(A)263K——263K
Jun 30, 2021Grant(A)10K——10K
Jun 30, 2021Grant(A)100K——100K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001192482-21-000618) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML